Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Bayer Identifier:
First received: August 31, 2009
Last updated: January 13, 2014
Last verified: January 2014

The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with haemophilia A under daily-life treatment conditions.

Condition Intervention
Blood Coagulation Disorders
Hemophilia A
Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Total consumption of FVIII [ Time Frame: After 12 months and after 24 months ] [ Designated as safety issue: No ]
  • Number of bleedings [ Time Frame: After 12 months and after 24 months ] [ Designated as safety issue: No ]
  • Kind of bleedings [ Time Frame: After 12 months and after 24 months ] [ Designated as safety issue: No ]
  • Continuation of therapy [ Time Frame: After 12 months and after 24 months ] [ Designated as safety issue: No ]
  • Overall assessment by the physician [ Time Frame: After 12 months and after 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adverse event collection [ Time Frame: After 12 months and after 24 months ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   None Retained


Enrollment: 105
Study Start Date: September 2009
Estimated Study Completion Date: February 2014
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Patients under daily life treatment receiving Kogenate according to local drug information.


Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The study population will consist of patients with a diagnosis of hemophilia A. Physicians should consult the full prescribing information for KOGENATE® FS before enrolling patients and familiarize themselves with the safety information in the product package label.


Inclusion Criteria:

  • Patients with diagnosis of hemophilia A, independent of age, treated with KOGENATE® FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE® FS. For pretreated patients with more than 100 exposure days an inhibitor assessment within three months prior to enrollment should be available; for pretreated patients with less than 100 exposure days an inhibitor assessment at baseline should be available.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00969319

Many locations, Mexico
Many locations, Venezuela
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Bayer Identifier: NCT00969319     History of Changes
Other Study ID Numbers: 14285, KG0802
Study First Received: August 31, 2009
Last Updated: January 13, 2014
Health Authority: Mexico: Ethics Committee
Venezuela: Ethics Committee

Keywords provided by Bayer:
Octocog alfa
Hemophilia A

Additional relevant MeSH terms:
Blood Coagulation Disorders
Hemostatic Disorders
Blood Coagulation Disorders, Inherited
Hemophilia A
Cardiovascular Diseases
Coagulation Protein Disorders
Genetic Diseases, Inborn
Hematologic Diseases
Hemorrhagic Disorders
Vascular Diseases
Factor VIII
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on November 25, 2014